FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study

Background Colorectal carcinoma (CRC) is widely treated by chemotherapy based on an intensely neurotoxic drug: oxaliplatin (OXL). We objective to evaluate prospectively the orofacial neurotoxicity during FLOX (fluorouracil + leucovorin + OXL) chemotherapy. Methods So, 46 patients with CRC were prosp...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2020-12, Vol.25 (12), p.2066-2074
Main Authors: de Albuquerque Ribeiro Gondinho, Priscilla, de Barros Silva, Paulo Goberlânio, Lisboa, Mário Roberto Pontes, Costa, Bruno Almeida, da Rocha Filho, Duílio Reis, Gifoni, Markus Andret Cavalcante, Lima, Marcos Venicio Alves, Junior, Roberto César Pereira Lima, Vale, Mariana Lima
Format: Article
Language:English
Subjects:
5-Fluorouracil
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Burning
Cancer Research
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Ear
Face
Female
Fluorouracil - administration & dosage
Humans
Incidence
Jaw
Leucovorin - administration & dosage
Longitudinal Studies
Male
Medicine
Medicine & Public Health
Middle Aged
Mouth
Mouth - drug effects
Neuropathy
Neurotoxicity
Neurotoxicity Syndromes - epidemiology
Neurotoxicity Syndromes - etiology
Oncology
Original Article
Oxaliplatin
Oxaliplatin - administration & dosage
Pain
Peripheral Nervous System Diseases - chemically induced
Peripheral Nervous System Diseases - epidemiology
Prospective Studies
Speech
Surgical Oncology
Vision
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Colorectal carcinoma (CRC) is widely treated by chemotherapy based on an intensely neurotoxic drug: oxaliplatin (OXL). We objective to evaluate prospectively the orofacial neurotoxicity during FLOX (fluorouracil + leucovorin + OXL) chemotherapy. Methods So, 46 patients with CRC were prospectively evaluated during FLOX chemotherapy by 3 cycles (C) of 6 weeks (W) each. We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale). Patients were asked the following concerning the severity (scores 0–5) of orofacial symptoms: jaw pain, eyelids drooping, throat discomfort, ear pain, tingling in mouth, difficulty with speech, burning or discomfort of the eyes, loss of any vision, feeling shock/pain down back and problems breathing. We summed the scores (0–50) and evaluated the clinicopathological data. Friedman/Dunn, Chi square and multinomial regression logistic tests were used (SPSS 20.0, p  
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-020-01757-z